Corcept Therapeutics stock analysis
Corcept Therapeutics (0I3Q) Share Price & Analysis
0I3Q Stock Chart & Stats
- Day’s Range
- $68.50 - $71.57
- 52-Week Range
- $28.67 - $126.57
- Previous Close
- $69.25
- Volume
- N/A
- Average Volume (3M)
- 708
- Market Cap
- $7.58B
- Enterprise Value
- $13.83B
- Total Cash (Recent Filing)
- $370.70M
- Total Debt (Recent Filing)
- $8.99M
- Price to Earnings (P/E)
- 46.3
- Beta
- -0.58
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- 1.12
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Product Adoption
Rapid growth across the established endocrinology business and newly launched Lifyorli indicates expanding commercial reach and demand. Increasing physician and patient adoption can support durable revenue gains as Corcept broadens its presence across endocrine and oncology markets.
Strong Cash Generation And Conservative Leverage
Robust free cash flow near net income, combined with minimal leverage, gives Corcept substantial financial flexibility. This supports continued investment in clinical development and commercialization while reducing refinancing pressure and the need to rely on external capital.
Broad Pipeline And Expanding Treatment Opportunities
Multiple programs across endocrinology, oncology, liver disease and ALS create opportunities to diversify beyond the current marketed portfolio. Advancing studies and planned trials could expand the addressable market and provide additional long-term growth drivers.
Bears Say
Operating Margin Compression
Lower operating profitability suggests that expenses or nonrecurring impacts are absorbing more of Corcept’s revenue growth. If this persists, earnings may scale less efficiently, limiting the benefit of strong sales momentum and reducing funds available for reinvestment.
Regulatory Uncertainty For Relacorilant
The prior complete response letter demonstrates that relacorilant’s approval path has encountered regulatory obstacles. Until the FDA review is resolved, the timing and commercial contribution of a potentially important Cushing’s and oncology growth driver remain uncertain.
Underdiagnosis Limits Market Expansion
Persistent underdiagnosis can constrain the number of patients identified and treated, even when clinical evidence and screening recommendations improve. Slow adoption of updated standards may therefore lengthen the time needed to convert disease awareness into durable demand.
Corcept Therapeutics News
0I3Q FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
What is Corcept Therapeutics’s market cap?
When is Corcept Therapeutics’s upcoming earnings report date?
How were Corcept Therapeutics’s earnings last quarter?
Is Corcept Therapeutics overvalued?
Does Corcept Therapeutics pay dividends?
What is Corcept Therapeutics’s EPS estimate?
How many shares outstanding does Corcept Therapeutics have?
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Corcept Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Corcept Therapeutics Stock Smart Score
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Joseph K. Belanoff
- Employees
- 730
- Website
- www.corcept.com
- Address
- 101 Redwood Shores Parkway, Redwood City, CA, 94065, US
Corcept Therapeutics (0I3Q) Earnings & Revenues
0I3Q Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with substantial revenue and net-income growth, record endocrinology performance, rapid Lifyorli adoption, positive clinical results and multiple advancing pipeline programs. The company also reiterated its 2026 revenue guidance and highlighted significant future opportunities in Cushing's syndrome, oncology, MASH and ALS. The main negatives were the prior complete response letter for relacorilant, the continuing underdiagnosis of hypercortisolism, the unmet need in platinum-resistant ovarian cancer and limited available information on a potential competing therapy.
View all GB:0I3Q earnings summaries0I3Q Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |











